多肽HM-3与吉西他滨联合用药治疗Lewis肺癌的研究

Antitumor Effects of Peptide HM-3 and Gemcitabine against Experimental Lewis Lung Cancer

检测HM-3与吉西他滨联合用药治疗实验性Lewis肺癌的活性是否优于单用两种药物。建立Lewis肺癌肿瘤模型,观察HM-3单用或与吉西他滨合用对Lewis肺癌生长的抑制作用,分别用Bürgi氏规律公式和金氏公式计算增效q值,评价合用的效应强度是否优于单用。结果显示HM-3与吉西他滨合用使抑瘤率有显著提高,其中G4、G5、G6组联合给药的肿瘤抑制率分别高达88.3%,89.4%,88.5%,与阴性组及G2、G3相比,有极显著差异(**P<0.01)。HM-3与吉西他滨合用的抑瘤效果强于单用,且根据Bürgi氏规律公式与金氏公式验证结果为协同作用。

To evaluate whether the treatment by combination of anti-tumor polypeptide HM-3 and gemcitabine of experimental Lewis lung cancer is more efficient than the treatment with either reagent alone. Experimental Lewis lung carcinoma model was set up to compare the anti-tumor activity by using HM-3 or gemcitabine alone or their combination,to calculate the synergistic value of q by Bürgi's law formula and Guinness rules respectively and to determine whether the effect of combination is better than either reagent alone. Treatment by combination of HM-3 and gemcitabine showed a better effect in tumor inhibition rate,in which the respective inhibition rate of G4,G5,G6 group were 88. 3%,89. 4% and 88. 5% respectively. And displayed a significant inhibitory effect compared with the control,G3 and G4(**P < 0. 01). The anti-tumor effect of combinatory usage of HM-3 and gemcitabine is better than that of either reagent alone. By analysis with Bürgi's law formula and Guinness rules,the improved effect was determined to be a synergistic effect of the two compounds.